Foley catheter vs. oral misoprostol to induce labour among hypertensive women in India: A cost-consequence analysis alongside a clinical trial. by Leigh, Simon et al.
Foley catheter vs. oral misoprostol to induce
labour among hypertensive women in India:
a cost-consequence analysis alongside a clinical
trial
S Leigh,a P Granby,a A Haycox,a S Mundle,b H Bracken,c V Khedikar,d J Mulik,b B Faragher,e
T Easterling,f MA Turner,g Z Alfirevic,g B Winikoff,c AD Weeksg
a University of Liverpool Management School, Liverpool, UK b Department of Obstetrics & Gynaecology, Government Medical College,
Nagpur, India c Gynuity Health Projects, New York, NY, USA d Daga Memorial Women’s Government Hospital, Nagpur, India e Medical
Statistics Unit, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK f Department of Obstetrics and
Gynecology, University of Washington, Seattle, WA, USA g Department of Women’s and Children’s Health, University of Liverpool, Liverpool
Women’s Hospital, Liverpool, UK
Correspondence: S Leigh, University of Liverpool Management School, Chatham Street, Liverpool L69 7ZH, UK. Email: sleigh@liv.ac.uk
Accepted 22 April 2018. Published Online 22 June 2018.
Objective To determine the effectiveness and economic impact of
two methods for induction of labour in hypertensive women, in
low-resource settings.
Design Cost-consequence analysis of a previously reported
multicentre, parallel, open-label randomised trial.
Setting & population A total of 602 women with a live fetus, aged
≥18 years requiring delivery for pre-eclampsia or hypertension, in
two public hospitals in Nagpur, India.
Methods We performed a formal economic evaluation alongside
the INFORM clinical trial. Women were randomised to receive
transcervical Foley catheterisation or oral misoprostol 25 mcg.
Healthcare expenditure was calculated using a provider-side
microcosting approach.
Main outcome measures Rates of vaginal this delivery within
24 hours of induction, healthcare expenditure per completed
treatment episode.
Results Induction with oral misoprostol resulted in a (mean
difference) $20.6USD reduction in healthcare expenditure [95%
CI () $123.59 () $72.49], and improved achievement of
vaginal delivery within 24 hours of induction, mean difference
10% [95% CI (2 to 17.9%), P = 0.016]. Oxytocin
administration time was reduced by 135.3 minutes [95% CI
(84.4–186.2 minutes), P < 0.01] and caesarean sections by 9.1%
[95% CI (1.1–17%), P = 0.025] for those receiving oral
misoprostol. Following probabilistic sensitivity analysis, oral
misoprostol was cost-saving in 63% of 5,000 bootstrap
replications and achieved superior rates of vaginal delivery,
delivery within 24 hours of induction and vaginal delivery within
24 hours of induction in 98.7%, 90.7%, and 99.4% of bootstrap
simulations. Based on univariate threshold analysis, the unit price
of oral misoprostol 25 mcg could feasibly increase 31-fold from
$0.24 to $7.50 per 25 mcg tablet and remain cost-saving.
Conclusion Compared to Foley catheterisation for the induction
of high-risk hypertensive women, oral misoprostol improves rates
of vaginal delivery within 24 hours of induction and may also
reduce costs. Additional research performed in other low-
resource settings is required to determine their relative cost-
effectiveness.
Keywords Cost-consequence, economics, hypertension, labour
induction, low-resource settings, pre-eclampsia.
Tweetable abstract Oral misoprostol less costly and more effective
than Foley catheter for labour induction in hypertension.
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Introduction
Hypertensive disorders, including pre-eclampsia, are the
most common medical complication of pregnancy,
accounting for ~14% of the estimated 303 000 global
annual maternal deaths.1,2 A great deal of this burden is
experienced in developing countries, where the incidence of
pre-eclampsia is increased considerably.3,4
Timely delivery, preferably by vaginal route, remains the
only definitive cure for pre-eclampsia and is therefore vital
to achieve favourable maternal and neonatal outcomes.
Hence, the induction of labour is a critical intervention in
the management of hypertension in pregnancy. Two low-
cost methods, low-dose oral misoprostol and the Foley bal-
loon catheter, have been previously recommended for the
induction of labour within low-resource settings, but are
yet to be directly compared.5
The prostaglandin E1 analogue oral misoprostol is a
highly effective induction agent;6 however, it carries a uter-
ine hyperstimulation rate of 5–10%,7 potentially resulting in
hypoxic damage to the fetus. Although evidence from low-
resource settings is scant, studies conducted in developed
health economies suggest Foley balloon catheterisation may
be equally effective as oral misoprostol for the induction of
labour, with lower rates of uterine hyperstimulation,8–10 but
also a slower speed of induction and increased requirement
for caesarean section.8 Induction with the Foley balloon
catheter may therefore result in a reduction of risk to the
fetus, but with the caveat of a slower labour and an
increased use of oxytocin. Because in many low-resource
settings, oxytocin is administered under gravity alone (using
drip counters), it is possible that any neonatal benefits from
Foley balloon induction may be outweighed by the compli-
cations of overdosage with oxytocin.
To date, the sum of available evidence suggests both
methods are promising; however, the relative cost-effective-
ness of these methods for induction of labour in women
with gestational hypertension remains unknown in low-
resource settings. We conducted a cost-consequence analysis
of a previously reported multicentre randomised controlled
trial (RCT),11 comparing oral misoprostol with Foley bal-
loon induction in women with gestational hypertension. We
compared the respective efficacy, healthcare resource utilisa-
tion, and adverse event profile of these therapeutic indica-
tions for the induction of labour among those with
gestational hypertension in a low-resource setting.
Materials & methods
Study design & Participants
We undertook a cost-consequence analysis of a previously
reported multicentre, parallel, open-label randomised trial
at two public hospitals in Nagpur, India, between
December 2013 and June 2015. The study was approved by
the Research Ethics Committees at Government Medical
College, and the University of Liverpool. As required by
the Drug Controller General of India, women provided
both written and video-recorded oral consent. The trial is
registered with the clinical trials registry ClinicalTrials.gov:
NCT01801410.
The trial protocol is published elsewhere.12 In short,
however, women requiring delivery for hypertension or
pre-eclampsia were randomised to either cervical ripening
with transcervical Foley catheter or 25 mcg oral misopros-
tol tablets given every 2 hours. Only women ≥18 years of
age with continuing pregnancies and a live fetus, in whom
the decision had been made to induce vaginal delivery
because of pre-eclampsia or hypertension, were eligible to
participate. Women unable to give informed consent and
those with a prior caesarean delivery, multiple pregnancy,
ruptured membranes, clinically diagnosed chorioamnioni-
tis, or a history of allergy to misoprostol were ineligible for
the trial.
Randomisation and masking
Women were informed about the study by their doctor
when the need for induction of labour occurred, and
enrolled by research staff on the labour ward on the day of
induction. After informed consent, a sequentially num-
bered, sealed, opaque envelope containing the participant’s
group assignment in a 1:1 ratio was opened by research
staff. The randomisation was stratified by centre and used
randomly assigned block sizes of 4, 6, and 8. Due to differ-
ences in administrative method between the two interven-
tions, the masking of intervention allocation would have
been very difficult and was therefore not performed.
Procedures/Interventions
Prior to randomisation, the resident doctor performed a dig-
ital examination, to establish a baseline Bishop score and cer-
vical dilation. Women randomised to the Foley catheter arm
underwent induction using a transcervical Foley catheter (sil-
icone, size 18F with 30-ml balloon). The catheter remained
in place until it was expelled when active labour started, or
alternatively, until 12 hours had elapsed, in which case an
artificial rupture of membranes (ARM) was performed, and
an oxytocin infusion commenced. Similarly, if the Foley
catheter fell out within 12 hours, the membranes were rup-
tured and an oxytocin infusion commenced.
Women assigned to the misoprostol group were induced
using oral misoprostol tablets (Cipla Misoprost 25 mcg),
every 2 hours for a maximum of 12 doses (24 hours) or
until active labour commenced. In primigravida women, if
contractions had not commenced after 2 doses, the dosage
could be increased to 50 mcg every 2 hours. Once in
labour (defined as regular painful contractions with a
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cervical dilation of at least 4 cm), no more misoprostol
was used and artificial membrane rupture and/or oxytocin
infusion was used as clinically indicated. In both arms, if
labour had not commenced after 24 hours, the case was
considered a ‘failed induction’ and the decision on further
management was made by the clinical team.
For women in both groups, oxytocin was administered
with a regular drip infusion set, monitored by counting the
number of drops per minute. One unit of oxytocin was
injected into 500 ml of Ringer’s lactate, started at a rate of
2 mU/minute (15 drops/minute), and increased every
30 minutes by 2 mU/min until there were three–four con-
tractions in ten minutes. All women were monitored by the
research staff on a one-to-one basis. Participants with sev-
ere hypertension received magnesium sulphate and antihy-
pertensives both before and after randomisation as per the
hospital protocol.
Outcomes
The primary clinical outcome of the clinical trial was the
achievement of vaginal delivery within 24 hours of induc-
tion. As such, our cost-consequence analysis considered the
comparative achievement of vaginal delivery, delivery (by
any method) within 24 hours of induction, and a composite
measure of vaginal delivery within 24 hours of commencing
induction. We also report the comparative ‘costs per suc-
cessful vaginal delivery within 24 hours of induction’, from
the perspective of the Indian healthcare system. Although
the study was neither designed nor statistically powered for
subgroup analyses, exploratory subgroup analyses were used
to highlight potentially important differences in the cost-
effectiveness of the two treatments, which could be attribu-
ted to differences in observable patient characteristics.
Healthcare expenditure was estimated by multiplying the
observed utilisation of healthcare resources, as recorded at
the patient’s bedside by trial administrators, by associated
unit costs obtained from the finance department of
Government Medical College, Nagpur, India. Because unit
costs were obtained in Indian rupees (INR) for the finan-
cial year of 2014/2015, costs were inflated using the con-
sumer price index, and then converted into US dollars
(USD) using a purchasing power parity-adjusted exchange
rate of 17.22INR to 1USD as estimated by the World
Bank.13 Because data were non-normally distributed, 95%
confidence intervals for treatment costs were imputed using
5,000 nonparametric gamma bootstrap simulations, fol-
lowed by the percentile method to define lower and upper
confidence limits. Sampling distributions were derived from
the observed mean and standard deviation of each cost
component (delivery, induction, inpatient, neonatal), for
each treatment group. All unit costs are reported in
Table S1. We additionally assessed the acceptability of each
induction method by asking participants about (1)
self-reported pain experienced, (2) acceptability with the
amount of time taken, and (3) whether participants would
use the same method for induction again.
Statistical analysis
We used summary statistics to describe the characteristics of
the trial groups at baseline. Categorical variables were sum-
marised by frequency and percentage, while continuous vari-
ables were reported as mean and standard deviation (SD).
We analysed data for the primary economic outcome from a
modified intention-to-treat (ITT) perspective, including all
randomly assigned participants, except for those in whom
primary outcome data were missing, due to withdrawal from
the trial postrandomisation. Normally distributed continu-
ous variables were compared using the Student t-test.
The sample size was estimated a priori, assuming a vagi-
nal delivery rate of 41% with the Foley catheter, based on
previously published data using identical induction proto-
cols and outcomes to this study.14–16 Full details of the
sample size calculation, in addition to data concerning the
occurrence of adverse events, which bore no clear and
translatable cost to the healthcare providers (e.g. headache,
maternal vomiting, and meconium-stained liquor), are
reported elsewhere.11
Results
Recruitment & Clinical efficacy
Between December 2013 and June 2015, 2,412 women were
assessed for eligibility, with 602 women included in the
trial (Figure S1). For a single patient, primary outcome
data were missing for the primary outcome, and for this
reason, this patient was excluded from the analysis, result-
ing in a total of 601 participants in a modified intention-
to-treat analysis. Baseline characteristics were similar for
the two groups, as shown in Table 1.
Those receiving oral misoprostol 25 mcg demonstrated
greater achievement of the primary clinical outcome of the
trial, with 57% [95% CI (51.4–62.5%)], as opposed to 47%
[95% CI (41.5–52.8%)] in the Foley group achieving a
vaginal delivery within 24 hours of induction (P = 0.0162).
Vaginal delivery was observed in 59.3% and 49.8% of
misoprostol and Foley patients, respectively (P = 0.0210),
while 92.5% of misoprostol and 89.3% of Foley patients
delivered within 24 hours of induction (P = 0.1913).
Determinants of costs, and treatment acceptability
Misoprostol patients incurred a mean treatment cost of
$117.5 during their hospital episode [95% CI $49.73–
$202.73], a 14.9%, or $20.6 reduction when compared to
those receiving Foley catheterisation, at $138.1 per patient
[95% CI $56.83–$246.66, P < 0.0001). Those randomised
to the Foley group incurred a mean induction cost of $26.4
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per patient [95% CI ($8.92–$50.91)], compared to $15.7
per patient [95% CI ($1.26–$39.67)] in those receiving oral
misoprostol. Most of this difference was attributable to a
significantly higher utilisation of oxytocin in the Foley
group (81.6% vs. 52%), an increased duration of oxytocin
administration (5.9 vs 2.5 hours per patient (P < 0.0001)),
and an increased use of artificial rupture of membranes
(77.2% vs. 60.7%, P = 0.001).
Delivery-related healthcare expenditure was reduced, on
average, by $2.3 (95% CI $1.34–$3.79) per patient in
those receiving oral misoprostol. This saving was attribu-
table, in the majority, to the significant reduction in
caesarean-section rate (50.3 vs. 41.1%, P = 0.025), and
spinal anaesthesia (50% vs. 41.1%, P = 0.0275) for oral
misoprostol patients, as demonstrated in Table 2.
Those undergoing Foley catheterisation also exhibited
higher inpatient costs than those receiving oral misoprostol.
The time between randomisation and commencing induc-
tion was almost four times greater for Foley patients (0.56 to
0.16 hours, P = 0.0004), while the time from induction to
delivery was reduced by approximately 90 minutes for those
receiving oral misoprostol (14.35 vs. 12.85 hours,
P = 0.0094). Additionally, in the postpartum period, patients
receiving oral misoprostol spent on average 11.4 hours fewer
in hospital prior to discharge (136.96 vs. 125.45 hours,
P = 0.0792). The costs of neonatal care were almost equiva-
lent in both groups, with a $3.3 saving (95% CI (-)$1.06–
$7.67) in favour of Foley catheterisation. Most women in
both groups found their assigned method of induction, and
the duration of the induction, to be acceptable, and the pain
they experienced to be either slight or moderate (Table 3).
More women in the misoprostol group (82.8%) than the
Foley catheter group (72%) would use the same method in
the future should they require another induction (Table 3;
P = 0.006).
Maternal and neonatal outcomes
No significant difference in adverse events was observed.
Uterine hyperstimulation occurred in 0.3% and 0.7% of the
Foley and misoprostol groups, respectively (P = 0.566). Sim-
ilarly, rates of fetal heart rate abnormality (5.7% vs. 4.0%),
severe hypertension (7.0% vs. 7.6%), postpartum haemor-
rhage (0.7% vs. 0.7%), and use of blood products after trial
entry (1.7% vs. 0.3%) were not statistically different. Two
Table 1. Baseline characteristics of study groups
Measure Foley catheter (n = 300) Misoprostol (n = 302)
Study site
GMC, n (%) 150 (50.0) 151 (50.0)
Daga, n (%) 150 (50.0) 151 (50.0)
Background
Woman’s age, mean (SD) [range] 24.0 (3.5) [18–42] 23.7 (3.1) [18–37]
Mother’s education
No formal education, n (%) 5 (1.7) 2 (0.7)
Primary, n (%) 86 (28.7) 112 (37.1)
Secondary, n (%) 149 (49.7) 131 (43.3)
University, n (%) 60 (20.1) 57 (19.0)
Medical history
Nulliparous (no previous pregnancies >28 weeks), n (%) 247 (82.3) 236 (78.1)
Previous hypertension in pregnancy: n (%) 8 (2.7) 16 (5.3)
Previous stillbirth, n (%) 1 (0.3) 5 (1.7)
Pre-existing diabetes/renal or liver disease, n (%) 0 0
Pre-existing chronic hypertension, n (%) 0 1 (0.3)
State at recruitment
Gestational age (best estimate in weeks), mean (SD) [range] 38.2 (2.2) [29–42] 38.1 (2.1) [29–41]
Estimate made by ultrasound at <20 weeks, n (%) 131 (43.7) 127 (42.1)
Systolic BP (mm/Hg), mean (SD) [range] 142.2 (11.3) [104–180] 142.8 (12.5) [102–190]
Diastolic BP (mm/Hg), mean (SD) [range] 95.0 (8.3) [60–130] 94.7 (8.3) [66–120]
Proteinuria at enrolment
Nil or trace, n (%) 156 (52.0) 162 (53.7)
+1 / +2, n (%) 122 (40.6) 121 (40.0)
+3 / +4, n (%) 22 (7.4) 19 (6.3)
Hypertensive symptoms at enrolment: n (%) 64 (21.3) 58 (19.2)
Woman received MgSO4 in last 12 hours, n (%) 45 (15.0) 42 (13.9)
Woman currently on antihypertensives, n (%) 292 (97.3) 289 (95.7)
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babies (1%) were stillborn to women induced with the Foley
catheter, and nine babies (1%) died in total, three in the
Foley group (all due to prematurity) and six in the misopros-
tol group (three due to prematurity, one from prematurity
plus intrauterine growth restriction, one from intrauterine
growth restriction alone, and one from asphyxia). The causes
of death did not differ significantly between the two groups.
Neonatal morbidity, as judged by Apgar scores, asphyxiation,
admission to special care units, ventilation, and oxygen
administration rates were similar in both groups, and further
details of the adverse event profile of each treatment are pro-
vided in Tables 3 and 4.
Sensitivity analysis
Following probabilistic sensitivity analysis, oral misoprostol
was cost-saving in 63% of 5,000 bootstrap replications.
Oral misoprostol also achieved superior rates of delivery
within 24 hours of induction, vaginal delivery, and vaginal
delivery within 24 hours of induction in 90.7%, 98.7%,
and 99.4% of bootstrap simulations. Based on univariate
threshold analysis, the unit price of oral misoprostol
25 mcg could feasibly increase 31-fold from $0.24 to $7.50
per 25 mcg tablet and still remain weakly dominant over
Foley catheterisation, resulting in equivalent costs and
improved rates of induction within 24 hours of labour.
Subgroup analyses
As expected, healthcare expenditure per completed treat-
ment episode increased with the extent of prematurity, as
shown in Table S2. Oral misoprostol demonstrated
resource savings over Foley catheterisation at all gestational
ages, in addition to demonstrating improved effectiveness,
the extent of which increased with the extent of prematu-
rity. For those with a Bishop’s score of ≥3, oral misoprostol
resulted in a $15.3 per patient reduction in treatment costs
and a 13% improvement in vaginal delivery within
Table 2. Utilisation rates and determinants of cost difference between Foley catheterisation and oral misoprostol 25 mcg
Foley catheterisation
(n = 299)
Cost per
patient ($)
Oral misoprostol
(n = 302)
Cost per
patient ($)
P-value
Induction-related determinants of costs
Antihypertensives (mg per person)
Nifedipine 8.96 $0.08 6.6 $0.06 0.1712
Aldomet 340.3 $0.28 351.8 $0.29 0.7169
Labetalol 14.7 $0.15 16.9 $0.17 0.5996
Antibiotics (mg per person)
Cifran IV 4.7 $0.03 0 $0.00 0.0346
Metronidazole IV 0 $0.00 2.7 $0.10 0.1576
Taxim IV 33.4 $0.95 33.1 $0.06 0.9853
Analgesics (mg per person)
Paracetamol 13.4 $0.01 11.6 $0.01 0.7792
Other
MgSO4 (gm per person)* 1.74 $1.47 1.69 $1.41 0.8972
Oxytocin (minutes of infusion per person) 432.3 $9.08 297 $4.12 0.000
ARM** 193 (77.2%) $8.21 153 (60.7%) $6.38 0.001
Delivery-related determinants of costs
Caesarean 150 (50.2%) $15.79 124 (41.1%) $12.93 0.025
Spinal anaesthesia 149 (49.8%) $15.69 124 (41.1%) $12.93 0.0308
Local anaesthesia 94 (31.4%) $3.98 114 (37.7%) $4.59 0.1968
Episiotomy*** 96 (64.4%) $4.05 118 (65.9%) $4.88 0.0891
Inpatient determinants of costs
Time (hours) from randomisation to induction 0.56 $0.19 0.16 $0.05 0.0001
Time (hours) from induction to delivery 14.35 $4.90 12.85 $4.38 0.0008
Time (hours) from delivery to discharge 136.96 $46.74 125.45 $42.81 0.1503
Total time as inpatient (hours) 151.86 $51.82 138.46 $47.25 0.0432
Neonatal determinants of costs
Ventilation (min) 50.05 $0.44 26.03 $0.23 0.736
Oxygen administration (min) 82.35 $0.36 86.62 $0.38 0.4165
NICU stay (min) 491.15 $4.35 548.24 $4.80 0.8087
*Including costs of fluids and intracatheters to administer MgSO4
**Out of those with rupture time recorded
***Out of 149 vaginal deliveries in Foley group vs. 179 vaginal deliveries in misoprostol group
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24 hours of induction (52% vs. 58.8%, P = 0.12). For those
with a Bishop’s score of <3, almost twice as many women
delivered vaginally within 24 hours in the oral misoprostol
cohort (45% vs. 22.7%) (P = 0.03), while healthcare expen-
diture was also reduced by $37.6 per patient.
Discussion
Main findings
The results of this multicentre randomised trial, performed
in two hospitals within the Maharashtra Province of India,
demonstrate that for the induction of hypertensive women
in low-resource settings, low-dose oral misoprostol 25 mcg
is both more clinically effective and less resource-intensive
than transcervical Foley catheterisation. 57% [95% CI
(51.4–62.5%)] of our oral misoprostol group, as opposed
to 47% [95% CI (41.5–52.8%)] in the Foley group,
achieved a vaginal delivery within 24 hours of induction
(P = 0.0162), while mean treatment costs equalled $138.10
per patient [95% CI $127.06–$146.28] in the Foley group,
reducing by 14.9% to $117.51 per patient [95% CI
$111.06–$123.45] in the oral misoprostol group. This $20.6
saving per patient could have provided a 40-hour stay in
ICU, or 77 hours of oxygen administration in this low-
Table 3. Maternal outcomes for those receiving Foley catheterisation and oral misoprostol 25 mcg
Foley catheter (n = 300) Oral misoprostol (n = 302) Mean difference (95% CI) P-value
Vaginal birth within 24 hours 141 (47%) 172 (57%) 10.0% (2.0 to 17.9) 0.0136
Delivered within 24 hours 268 (89.3%) 279 (92.4%) 3.1% (1.5 to 7.6) 0.194
Vaginal birth 149 (49.7%) 178 (58.9%) 9.3% (1.3 to 17.2) 0.0212
Mode of birth
Spontaneous vaginal birth 146 (48.7%) 176 (58.3%) 9.6% (1.7 to 17.5) 0.0194
Forceps or vacuum birth 3 (1%) 2 (0.7%) 0.3% (1.8 to 1.1)
Caesarean section 151 (50.3%) 124 (41.1%) 9.2% (17.2 to 1.3) 0.025
Oxytocin required 244 (81.6%) 157 (52%) 29.6% (36.8 to 22.5) <0.0001
Hours of oxytocin 5.9 2.5 3.4 (2.7 to 4.1) <0.0001
Total time spent in hospital 151.6 138.4 13.2 (2.9 to 29.2) 0.0537
Randomisation to induction 0.56 0.16 0.4 (0.17 to 0.63) 0.0004
Induction to delivery 14.3 12.9 1.4 (0.2 to 2.6) 0.0094
Delivery to discharge 136.8 125.4 11.4 (4.4 to 27.1) 0.0792
Analgesia
Spinal anaesthesia 150 (50%) 124 (41.1%) 8.9% (16.9 to 1.0) 0.0275
Local anaesthesia 94 (31.3%) 114 (37.7%) 6.4% (1.2 to 14.0) 0.097
Complications of labour and birth
Uterine hyperstimulation 1 (0.3%) 2 (0.7%) 0.3% (0.8 to 1.5) 0.566
Fetal heart rate abnormality 17 (5.7%) 12 (4%) 1.7% (5.1 to 1.7) 0.332
Diagnosis of postpartum haemorrhage 2 (0.7%) 2 (0.7%) 0 (1.3 to 1.3) 0.995
Blood products after trial entry 5 (1.7%) 1 (1.3%) 1.3% (2.9 to 03) 0.099
Severe hypertension 21 (7%) 23 (7.6%) 0.6% (3.5 to 4.8) 0.772
Any form of complication 44 (14.7%) 37 (12.3%) 2.4% (7.9 to 3.0) 0.385
Adverse effects during induction
Mild diarrhoea 2 (0.7%) 7 (2.3%) 1.7% (0.3 to 3.6) 0.094
Amount of pain experienced
None/slight 91 (30.3%) 86 (28.5%)
Moderate 145 (48.3%) 152 (50.3%)
High/extreme 64 (21.3%) 64 (21.2%)
Acceptability of amount of time taken
Very acceptable 49 (16.4%) 52 (17.2%)
Acceptable 129 (43.1%) 145 (48.0%)
Neutral 81 (27.1%) 75 (24.8%)
Unacceptable 35 (11.7%) 26 (8.6%)
Very unacceptable 5 (1.7%) 4 (1.3%)
Would use same method again?
Yes 216 (72%) 250 (82.8%)
No 59 (19.7%) 35 (11.6%) 0.006
No preference 25 (8.3%) 17 (6%)
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resource setting. Sensitivity analysis demonstrated a 63%
probability of oral misoprostol being cost-saving over Foley
catheterisation, and a 90.7%, 98.7%, and 99.4% probability
of achieving superior rates of delivery within 24 hours of
induction, vaginal delivery, and vaginal delivery within
24 hours of induction, respectively.
Strengths & limitations
A key strength of this study is that to the best of our col-
lective knowledge, it is the first of its kind to demonstrate
the relative cost-effectiveness and budget impact of these
two treatments for the induction of labour in hypertensive
women. Additionally, the study relied upon internally col-
lected financial data concerning real-world purchasing and
reimbursement costs for the hospitals involved, while all
observations concerning patient-level resource use were col-
lected at the patient’s bedside via trial administrators,
resulting in considerable precision.
The limitations of this study primarily concern the real-
world validity of several assumptions. First, outside of trial
conditions, it is unclear whether midwives would have the
capacity to continuously provide oral misoprostol at opti-
mal two-hourly intervals. As such, the efficacy of oral miso-
prostol demonstrated within this trial may be greater than
that which we would expect to observe in the real world.
Second, the financial costs of staff time, whether nurse,
junior doctor, or consultant, were accounted for on an
equal basis, due to the unavailability of data concerning
individual staff salaries. While oral misoprostol can be
administered by most staff members, a greater skill level is
necessary to insert a Foley catheter, suggesting that the
costs of Foley insertion were possibly underestimated dur-
ing this analysis. Third, hospitals vary hugely in their
approach to intrapartum protocols. The oral misoprostol
and Foley catheter protocols described in this study are
based on previous studies, guidelines, and expert advice.
However, they are not the definitive versions, and the costs
(and clinical outcomes) could vary considerably with even
small variations in indication, oxytocin use, or staff super-
vision. Settings both within India and internationally will
also vary in their rates of caesarean section and costs of
neonatal care, and these could have marked effects on the
cost-effectiveness. The results of this study can only there-
fore be viewed as an indication of what happens with a
typical protocol and hospital setting. Of particular note is
the absence of intrapartum continuous electronic monitor-
ing and electronic oxytocin pumps. This increases its appli-
cability and generalisability to other low-resource settings
without these technologies, but limits its applicability to
settings where these technologies are more readily available.
Table 4. Neonatal outcomes for those receiving Foley catheterisation and oral misoprostol 25 mcg
Foley catheter (n = 300) Oral misoprostol (n = 302) Mean difference (95% CI) P-value
Outcome of birth
Live birth 298 (99.3%) 302 (100%) 0.70%
Stillbirth 2 (0.7%) 0
Birthweight (g)
Mean (SD) 2612 (464) 2616 (490) 4 (72 to 80) 0.918
Median (Range) 2600 (1000–3830) 2600 (750–3800)
Apgar score at 1 minute
<7 10 (3.4%) 12 (4%) 0.6% (2.4 to 3.6) 0.687
>7 288 (96.6%) 290 (96%)
Apgar score at 5 minutes
<7 1 (0.3) 6 (2%) 1.7% (0.1 to 3.4) 0.058
>7 297 (99.7%) 296 (98%)
Apgar score at 10 minutes
<7 0 5 (1.7%) 1.70% 0.431
>7 298 (100%) 297 (98%)
Other neonatal outcomes
Neonatal death 3 (1%) 6 (2%) 1.0% (1.04 to 2.97) 0.322
Baby admitted to special care nursery 19 (6.4%) 28 (9.3%) 2.9% (1.4 to 7.2) 0.186
Baby given oxygen 33 (11.1%) 42 (13.9%) 2.8 (2.5 to 8.1) 0.293
Baby ventilated 4 (1.3%) 4 (1.3%) 0 (1.9 to 1.8) 0.985
Sarnat score completed 19 (6.3%) 29 (9.6%) 3.3% (1.0 to 7.6) 0.138
Normal 13 (68.4%) 20 (69%)
Moderate 6 (31.6%) 8 (27.6%)
Severe 0 1 (3.4%)
7ª 2018 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of
Royal College of Obstetricians and Gynaecologists
Inducing labour in hypertension: Foley catheter vs. oral misoprostol
Interpretation in the light of other evidence
The induction of labour is a critical intervention in the
management of hypertension in pregnancy. Two low-cost
methods, low-dose oral misoprostol and the Foley balloon
catheter, have been previously recommended for the induc-
tion of labour within low-resource settings, with both
found to have advantages over other induction methods in
systematic reviews,6–8,10 but until recently, they had never
been directly compared.
Due to a lack of effect on uterine contractions during
the cervical ripening phase,8,10 Foley catheterisation has
been shown to result in safe but slow labours, which avoid
the dangers of hyperstimulation, but may result in
increased requirement for both caesarean section8 and
additional need for labour augmentation with oxytocin.
This was observed within our study, with 57% of miso-
prostol and 47% of Foley patients achieving a successful
induction. As a result, over 80% of our Foley cohort
required additional uterine stimulation with oxytocin in
comparison with just 52% of the misoprostol cohort, a
finding synonymous with existing literature.10 Furthermore,
among those who did require oxytocin infusion, the dura-
tion of infusion also increased by 57% for those in the
Foley group (432.3 vs. 297 minutes). This resulted in a
greater use of limited healthcare resources during the
induction interval. Furthermore, because in many low-
resource settings, oxytocin is administered under gravity
alone, without the safeguards of electronic infusion control,
any reduction in oxytocin usage may not only reduce
health service costs, but also improve maternal safety, with
the risks associated with oxytocin overdosage falling.
Additionally, given the increased susceptibility for failed
inductions, literature collected in Western settings has
demonstrated that caesarean-section rates may be higher in
those induced with the Foley balloon catheter, when com-
pared to other induction methods,8, 17 and the results of
this study, performed in a low-resource setting, corroborate
this finding. Those receiving the Foley catheter experienced
an 18.1% increase in caesarean-section rates relative to
those receiving oral misoprostol, suggesting that not only is
the use of Foley catheterisation in this setting likely to result
in an escalation of risk to patients, given considerations of
infection control and the general risks of anaesthesia, but
also likely to increase pressures on nursing staff, hospital
beds, and highly skilled theatre technicians, all of which are
likely already in both high demand and short supply.
Given the high prevalence of pre-eclampsia,1,2,18 in addi-
tion to low levels of investment in publicly funded health
care in India (1.3% of GDP),19,20 the discovery that oral
misoprostol results in both improvements in clinical out-
comes and reductions in healthcare expenditure is an
important finding. The $5,611.4222 difference in total
healthcare expenditure between the two arms of this trial
over the study period could have otherwise provided 89
caesarean sections, 445 days in a special care baby unit, or
3,563 bags of saline solution. As such, the opportunity for
similar savings to be achieved on a larger scale, which
could then be used to promote health where unmet clinical
need is greatest, could have considerable impact.
Further research should aim to determine whether the
results observed in this province of India are generalisable
to other provinces or low-resource settings, and whether
widening the inclusion criteria to better reflect routine clini-
cal practice, including those with a prior C-section, would
change the study conclusions. There are a wide variety of
induction methods available, but this study relates only to
these two specific methods. For example, some practitioners
are using the Foley catheter at the same time as low-dose
misoprostol to improve outcomes, and this also deserves
further research. Widening the perspective of the analysis
beyond solely health-service-related outcomes would also
provide valuable insights as to the societal impact of each
treatment indication, particularly with respect to time away
from work, impact on ability to perform household duties,
and the financial costs of birthing partners requiring accom-
modation for the duration of hospital stay.
Conclusion
The results of this study suggest that when compared to
Foley catheterisation for the induction of high-risk hyper-
tensive women, oral misoprostol improves rates of vaginal
delivery, delivery within 24 hours of induction, and vaginal
delivery within 24 hours of induction and may also reduce
costs. Additional research performed in other low-resource
settings is essential to determine the definitive cost-effec-
tiveness of these two treatments.
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